2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Frontiers in Pharmacology FRONT PHARMACOL LetPub评分 7.8
79人评分
我要评分
声誉 8.3 影响力 7.0 速度 8.6 | |||||||||||||||||||||
| 期刊ISSN | 1663-9812 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 6.20%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 62 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. | |||||||||||||||||||||
| 期刊官方网站 | http://journal.frontiersin.org/journal/pharmacology | |||||||||||||||||||||
| 期刊投稿网址 | http://www.frontiersin.org/submission/submissioninfo.aspx | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Frontiers in Pharmacology的语言要求，还能让Frontiers in Pharmacology编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Frontiers in Pharmacology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2950; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：pharmacology、pharmaceutics、ethnopharmacology、experimental pharmacology、neuropharmacology 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardBlind peer review | |||||||||||||||||||||
| 通讯方式 | AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015 | |||||||||||||||||||||
| 出版商 | Frontiers Media S.A. | |||||||||||||||||||||
| 涉及的研究方向 | PHARMACOLOGY & PHARMACY- | |||||||||||||||||||||
| 出版国家或地区 | SWITZERLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 3824注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 99.16% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 74.42% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1663-9812%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 14 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Frontiers in Pharmacology顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions. Author: Shao R1,2, Wang FJ1,2, Lyu M1,2, Yang J1,2, Zhang P1,2, Zhu Y1,2. Journal: Front Pharmacol. 2019 Apr 24;10:412. doi: 10.3389/fphar.2019.00412. eCollection 2019. PubMed DOI |
| 2. | Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders. Author: Ren Q1,2. Journal: Front Pharmacol. 2019 Apr 24;10:420. doi: 10.3389/fphar.2019.00420. eCollection 2019. PubMed DOI |
| 3. | TRPV1 Channel Contributes to the Behavioral Hypersensitivity in a Rat Model of Complex Regional Pain Syndrome Type 1. Author: Hu Q1, Wang Q2, Wang C2, Tai Y3, Liu B1, Shao X1, Fang J1, Liu B1. Journal: Front Pharmacol. 2019 Apr 26;10:453. doi: 10.3389/fphar.2019.00453. eCollection 2019. PubMed DOI |
| 4. | Extract of Plantago asiatica L. Seeds Ameliorates Hypertension in Spontaneously Hypertensive Rats by Inhibition of Angiotensin Converting Enzyme. Author: Tong RC1, Qi M1, Yang QM1, Li PF1, Wang DD1, Lan JP1,2, Wang ZT1, Yang L1,2. Journal: Front Pharmacol. 2019 Apr 30;10:403. doi: 10.3389/fphar.2019.00403. eCollection 2019. PubMed DOI |
| 5. | USP7: Novel Drug Target in Cancer Therapy. Author: Wang Z1,2,3, Kang W1,2, You Y1,2, Pang J1,2, Ren H1,2, Suo Z3, Liu H1,2, Zheng Y1,2. Journal: Front Pharmacol. 2019 Apr 30;10:427. doi: 10.3389/fphar.2019.00427. eCollection 2019. PubMed DOI |
| 6. | Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota. Author: Zhang Y1, Geng J1, Hong Y1, Jiao L1, Li S1, Sun R1, Xie Y1, Yan C1, Aa J1, Wang G1. Journal: Front Pharmacol. 2019 Apr 30;10:440. doi: 10.3389/fphar.2019.00440. eCollection 2019. PubMed DOI |
| 7. | Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. Author: Zhou H1, Fu X1, Li Q1, Niu T1. Journal: Front Pharmacol. 2019 May 1;10:387. doi: 10.3389/fphar.2019.00387. eCollection 2019. PubMed DOI |
| 8. | Regulation of Wnt Singaling Pathway by Poly (ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Lung Cancer in Mice Induced by Benzo(a)pyrene Inhalation Exposure. Author: Dai W1,2, Fu Y1, Deng Y1, Zeng Z1, Gu P1, Liu H1, Liu J1, Xu X1, Wu D1, Luo X1, Yang L1, Zhang J1, Lin K1, Hu G2,3, Huang H1. Journal: Front Pharmacol. 2019 May 3;10:338. doi: 10.3389/fphar.2019.00338. eCollection 2019. PubMed DOI |
| 9. | Interaction Mechanisms Between the NOX4/ROS and RhoA/ROCK1 Signaling Pathways as New Anti- fibrosis Targets of Ursolic Acid in Hepatic Stellate Cells. Author: Huang C1, Gan D2, Luo F1, Wan S1, Chen J3, Wang A1, Li B1, Zhu X1. Journal: Front Pharmacol. 2019 May 3;10:431. doi: 10.3389/fphar.2019.00431. eCollection 2019. PubMed DOI |
| 10. | In silico Identification and Mechanism Exploration of Hepatotoxic Ingredients in Traditional Chinese Medicine. Author: Wu Q1,2,3, Cai C1,2, Guo P1, Chen M2, Wu X4, Zhou J1, Luo Y1, Zou Y2, Liu AL5, Wang Q1, Kuang Z2, Fang J1,4. Journal: Front Pharmacol. 2019 May 3;10:458. doi: 10.3389/fphar.2019.00458. eCollection 2019. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共52条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
